JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

JNJ

154.59

+0.68%↑

ABBV

189.81

+1.12%↑

NVO

74.6

+2.39%↑

UNH

299.22

-0.23%↓

ABT

133.52

-0.04%↓

Search

Eli Lilly and Co.

Abrir

SetorSaúde

766.13 0.37

Visão Geral

Variação de preço das ações

24h

Atual

Mín

759.04

Máximo

772.32

Indicadores-chave

By Trading Economics

Rendimento

-6.1B

2.8B

Vendas

-804M

13B

P/E

Médio do Setor

60.989

51.198

EPS

3.34

Rendimento de Dividendos

0.8

Margem de lucro

21.678

Funcionários

47,000

EBITDA

-2B

4.2B

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+30.26% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

0.80%

2.40%

Próximos Ganhos

6 de ago. de 2025

Próxima data de dividendos

10 de jun. de 2025

Próxima data de ex-dividendo

14 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-157B

671B

Abertura anterior

765.76

Fecho anterior

766.13

Sentimento de Notícias

By Acuity

36%

64%

119 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Eli Lilly and Co. Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de mai. de 2025, 14:41 UTC

Aquisições, Fusões, Aquisições de Empresas

Eli Lilly to Acquire SiteOne Therapeutics for Up to $1 Billion

1 de mai. de 2025, 11:24 UTC

Ganhos

Eli Lilly 1Q Revenue Surges on Demand for Mounjaro, Other Weight-Loss Treatments

29 de mai. de 2025, 01:00 UTC

Principais Notícias

How Ozempic's Maker Lost Its Grip on the Obesity Market It Created -- WSJ

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New -2-

28 de mai. de 2025, 18:09 UTC

Ganhos

Heart Disease Could Be a Goner When These New Drugs Arrive -- Barrons.com

27 de mai. de 2025, 14:02 UTC

Aquisições, Fusões, Aquisições de Empresas

Eli Lilly: SiteOne Deal Includes Phase-2-Ready STC-004 for Treatment of Pain >LLY

27 de mai. de 2025, 14:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Eli Lilly: SiteOne Deal Includes Upfront, Milestone Payments >LLY

27 de mai. de 2025, 14:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Eli Lilly to Buy SiteOne Therapeutics For Up to $1 Billion in Cash >LLY

27 de mai. de 2025, 14:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Lilly To Expand Its Pain Pipeline With Acquisition Of SiteOne Therapeutics >LLY

20 de mai. de 2025, 14:08 UTC

Ganhos

Novo Nordisk Woes Weigh on Denmark's Economy. Here's How. -- Barrons.com

12 de mai. de 2025, 22:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 de mai. de 2025, 18:45 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 de mai. de 2025, 17:14 UTC

Principais Notícias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

7 de mai. de 2025, 17:01 UTC

Principais Notícias

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 de mai. de 2025, 13:56 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

7 de mai. de 2025, 11:18 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. It Cuts Guidance as Weight-Loss Drug Sales Slow. -- Barrons.com

7 de mai. de 2025, 09:30 UTC

Principais Notícias

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

6 de mai. de 2025, 20:30 UTC

Principais Notícias

Novo Nordisk Reports Earnings Soon. The Wegovy Manufacturer Is Scrambling to Hold Market Share. -- Barrons.com

4 de mai. de 2025, 04:05 UTC

Aquisições, Fusões, Aquisições de Empresas

UnitedHealth's Stock Is Ailing. A Bigger Business Hasn't Helped. -- Barrons.com

1 de mai. de 2025, 21:07 UTC

Conversa de Mercado

Weight-Loss Drug Competitive Pressures Hammer Eli Lilly Shares -- Market Talk

1 de mai. de 2025, 14:07 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 de mai. de 2025, 12:47 UTC

Ganhos

These Stocks Are Moving the Most Today: Microsoft, Meta, Tesla, Apple, CVS, Eli Lilly, McDonald's, Moderna, and More -- Barrons.com

1 de mai. de 2025, 12:00 UTC

Principais Notícias

Lower Taxes Could Bring More Drug Production to U.S., Says Eli Lilly CEO -- WSJ

1 de mai. de 2025, 11:58 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 de mai. de 2025, 11:06 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 de mai. de 2025, 10:48 UTC

Ganhos

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

1 de mai. de 2025, 10:48 UTC

Ganhos

Eli Lilly Sees FY Rev $58.0B-$61.0B >LLY

1 de mai. de 2025, 10:45 UTC

Ganhos

Eli Lilly 1Q Adj EPS $3.34 >LLY

1 de mai. de 2025, 10:45 UTC

Ganhos

Eli Lilly Sees FY EPS $20.17-EPS $21.67 >LLY

1 de mai. de 2025, 10:45 UTC

Ganhos

Eli Lilly 1Q Net $2.76B >LLY

Comparação entre Pares

Variação de preço

Eli Lilly and Co. Previsão

Preço-alvo

By TipRanks

30.26% parte superior

Previsão para 12 meses

Média 997.6 USD  30.26%

Máximo 1,190 USD

Mínimo 700 USD

Com base em 20 analistas de Wall Street que oferecem metas de preço de 12 meses para Eli Lilly and Co. - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

20 ratings

17

Comprar

2

Manter

1

Vender

Pontuação Técnica

By Trading Central

N/A / 884.54Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Strong Bearish Evidence

Sentimento

By Acuity

119 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Eli Lilly and Co.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.